私募股权机构GI Partners完成对Charles River旗下CDMO和细胞解决方案业务的收购，并成立Rose BioSolutions-动脉网

GI Partners Completes Acquisition of the CDMO and Cell Solutions Businesses from Charles River Laboratories and forms Rose BioSolutions

PR Newswire 等信源发布 2026-05-07 20:59



可切换为仅中文







Creates Standalone Leader in Advanced Therapy Manufacturing with Decades of Proven Experience and Continued Commitment to Client Service

在先进治疗制造领域创建了拥有数十年经验证明经验和持续致力于客户服务的独立领导者

Dedicated Resources and Backing from GI Partners to Drive Innovation and Introduce New Capabilities

GI Partners的专用资源和支持将推动创新并引入新能力

SAN FRANCISCO

旧金山

，

May 7, 2026

2026年5月7日

/PRNewswire/ -- GI Partners, a leading private investment firm, today announced it has completed the acquisition of the Contract Development and Manufacturing Organization (CDMO) and Cell Solutions businesses from Charles River Laboratories International, Inc., forming Rose BioSolutions ('Rose Bio'), a leading provider of advanced manufacturing capabilities across the cell and gene therapy space..

/PRNewswire/ -- 领先的私人投资公司GI Partners今日宣布，已完成从查尔斯河实验室国际公司（Charles River Laboratories International, Inc.）收购合同开发与制造组织（CDMO）及细胞解决方案业务，成立了罗斯生物解决方案公司（Rose BioSolutions，简称“罗斯生物”），该公司是细胞和基因治疗领域先进制造能力的领先提供商。

As an independent company, Rose Bio is purpose-built to deliver end-to-end advanced therapy solutions for clients, providing CDMO's full-service development and manufacturing capabilities across plasmid DNA, viral vector, and cell therapy capabilities, as well as Cell Solutions' ability to deliver the cellular materials that research and advanced therapies depend on..

作为一家独立公司，Rose Bio 旨在为客户提供端到端的先进治疗解决方案，提供 CDMO 全方位的开发和制造能力，涵盖质粒 DNA、病毒载体和细胞治疗能力，以及 Cell Solutions 提供研究和先进疗法所依赖的细胞材料的能力。

The transaction positions Rose Bio to pursue its growth strategy focused solely on cell and gene therapy, leveraging its new structure and the expertise and resources of GI Partners, to invest in innovation, develop new capabilities, improve operational efficiency, and accelerate delivery timelines.

此次交易使Rose Bio能够专注于细胞和基因治疗的增长战略，利用其新结构以及GI Partners的专业知识和资源，投资于创新，开发新能力，提高运营效率，并加快交付时间。

Guided by its R.O.S.E. standard, the company is committed to Reliable, Outcome-driven, Scalable, and Excellent client service across every partnership and relationship..

公司以R.O.S.E.标准为指导，致力于在每一次合作与关系中提供可靠、结果导向、可扩展且卓越的客户服务。

'Our vision for the launch of Rose Bio was to create an independent company dedicated to cell and gene therapy development and manufacturing, building on the scientific expertise and strong operational track record of the CDMO and Cell Solutions businesses,' said Dave Kreter, Managing Director and Head of Healthcare Investments at GI Partners.

“我们对Rose Bio推出的愿景是创建一家独立的公司，专注于细胞和基因治疗的开发与制造，依托CDMO和Cell Solutions业务的科学专业知识及强大的运营记录，”GI Partners的董事总经理兼医疗保健投资主管Dave Kreter表示。

'Rose Bio fills a gap in the market for a truly end-to-end partner where every step, from starting materials to finished therapy, is part of a single, comprehensive offering. We understand the complexities of the life sciences sector, an industry where we have deep experience, and are well positioned to support the long-term, sustained growth of this platform.

“Rose Bio填补了市场上一个真正的端到端合作伙伴的空白，每一步，从起始材料到最终治疗，都是单一综合服务的一部分。我们了解生命科学领域的复杂性，这是我们拥有深厚经验的行业，并且我们有能力支持这一平台的长期可持续增长。

We are excited to invest in the infrastructure and world-class team to support the company's consistent execution and accelerate innovation.'.

我们很高兴投资于基础设施和世界级团队，以支持公司的持续执行并加速创新。

'We are grateful to the CDMO and Cell Solutions leadership teams for their ongoing support as we enter this next chapter together as Rose Bio. Their collective efforts have helped create a strong foundation for continued growth, and we are confident the organization is positioned to deliver a seamless transition for customers and teams.

“我们非常感谢CDMO和Cell Solutions领导团队的持续支持，随着我们共同进入Rose Bio的下一个篇章。他们的共同努力为持续增长奠定了坚实的基础，我们相信公司有能力为客户和团队提供无缝过渡。

We also appreciate the strong support Charles River has provided through this process, and we look forward to maintaining a long-term and mutually beneficial commercial relationship with Charles River,' continued Mr. Kreter..

“我们还感谢查尔斯河公司在此过程中提供的大力支持，我们期待与查尔斯河公司保持长期且互利的商业关系，”克雷特先生继续说道。

'Demand for advanced therapies continues to grow, underscoring the importance of having a trusted partner at all stages of the research, development, and manufacturing processes and making our solutions and expertise more important than ever before,' said Ahmad Hussin, Global Head of CDMO and Chief Operating Officer at Rose Bio.

“对先进疗法的需求持续增长，突显了在研究、开发和生产过程的各个阶段拥有可信赖合作伙伴的重要性，这使得我们的解决方案和专业知识比以往任何时候都更加重要，”罗斯生物CDMO全球主管兼首席运营官艾哈迈德·侯赛因表示。

'By bringing together one of the industry's broadest portfolios of cellular starting materials with world-class manufacturing capabilities across cell therapies, viral vectors, and plasmid DNA, we are well positioned to deliver comprehensive solutions with the reliability, quality, and scale our customers need to move programs forward and bring therapies to patients.' .

“通过将行业内最广泛的细胞起始材料之一与在细胞治疗、病毒载体和质粒DNA领域世界一流的制造能力相结合，我们已做好充分准备，为客户提供可靠、高质量且规模化的全面解决方案，推动项目进展并将治疗药物带给患者。”

In connection with the transaction, Moelis & Company LLC served as exclusive financial advisor to GI Partners, with Ropes & Gray LLP serving as legal counsel.

在本次交易中，Moelis & Company LLC 担任 GI Partners 的独家财务顾问，Ropes & Gray LLP 担任法律顾问。

About GI Partners

关于GI合伙人

Founded in 2001, GI Partners is a private investment firm with over 180 employees and offices in San Francisco, New York, Dallas, Chicago, Greenwich, Scottsdale, and London. The firm has raised more than $49 billion and invests on behalf of leading institutional investors around the world through its private equity, real estate, and data infrastructure strategies.

成立于2001年的GI Partners是一家私人投资公司，拥有超过180名员工，并在旧金山、纽约、达拉斯、芝加哥、格林威治、斯科茨代尔和伦敦设有办事处。该公司已筹集超过490亿美元的资金，并通过其私募股权、房地产和数据基础设施策略代表全球领先的机构投资者进行投资。

The private equity team invests primarily in companies in the healthcare, services, and software sectors. The real estate team focuses primarily on technology and healthcare properties as well as other specialized types of real estate. The data infrastructure team invests primarily in hard asset infrastructure businesses underpinning the digital economy.

私募股权团队主要投资于医疗保健、服务和软件行业的公司。房地产团队重点关注技术型和医疗型地产以及其他专业类型的房地产。数据基础设施团队则主要投资于支撑数字经济的硬资产基础设施业务。

For more information, please visit .

有关更多信息，请访问。

www.gipartners.com

。

About Rose BioSolutions

关于罗斯生物解决方案

Rose BioSolutions is a leading provider of development and advanced manufacturing capabilities across the cell and gene therapy space. As a full-service CDMO, Rose Bio is purpose-built to deliver end-to-end solutions for clients on industry-leading timelines and offers manufacturing across the full suite of plasmid DNA, viral vector, and cell therapies, as well as cell supply operations.

罗斯生物解决方案公司是细胞和基因治疗领域开发和先进制造能力的领先提供商。作为一家全方位服务的合同开发与制造组织（CDMO），罗斯生物旨在为客户提供行业领先的端到端解决方案，并在质粒DNA、病毒载体、细胞治疗以及细胞供应运营的全系列产品上提供生产服务。

Rose Bio operates facilities in Rockville, Maryland; Memphis, Tennessee; Northridge, California; and Keele, United Kingdom. For more information, please visit .

罗斯生物公司在马里兰州罗克维尔、田纳西州孟菲斯、加利福尼亚州北岭和英国基尔运营设施。欲了解更多信息，请访问。

rosebiosolutions.com

玫瑰生物解决方案.com

。

Media Contacts

媒体联系人

GI Partners:

GI合作伙伴：

[email protected]

电子邮件地址

Rose BioSolutions:

玫瑰生物解决方案：